Table 2.
Secondary efficacy endpoints.
| Variables | Dulaglutide Combined with CRD Therapy, LS Mean Change (95% CI) (n = 35) |
CRD Therapy, LS Mean Change (95% CI) (n = 33) |
LS Mean Difference between Groups (95% CI) |
p |
|---|---|---|---|---|
| Weight (kg) | −5.42 (−5.79 to −5.05) | −5.44 (−5.84 to −5.04) | 0.02 (−0.53 to 0.57) | 0.945 |
| WC (cm) | −4.34 (−5.55 to −3.14) | −3.61 (−5.05 to −2.17) | −0.73 (−2.61 to 1.15) | 0.435 |
| BMI (kg/m2) | −2.06 (−2.25 to −1.87) | −2.23 (−2.43 to −2.02) | 0.17 (−0.11 to 0.45) | 0.232 |
| Menstrual Cycles (no./yr) | 0.42 (0.01 to 0.83) | 0.79 (0.32 to 1.26) | −0.37 (−0.99 to 0.25) | 0.236 |
| SBP (mmHg) | −9.29 (−13.27 to −5.30) | −6.04 (−10.58 to −1.51) | −3.24 (−9.30 to 2.81) | 0.284 |
| DBP (mmHg) | −7.30 (−10.36 to −4.23) | −6.44 (−9.93 to −2.95) | −0.86 (−5.52 to 3.80) | 0.711 |
| FPG (mmol/L) | −0.30 (−0.50 to −0.10) | −0.07 (−0.29 to 0.15) | −0.23 (−0.53 to 0.07) | 0.131 |
| PPG (mmol/L) | −2.12 (−2.82 to −1.41) | −0.86 (−1.65 to −0.08) | −1.26 (−2.31 to −0.20) | 0.021 |
| FINS (mU/L) | −7.33 (−12.14 to −2.51) | −7.37 (−12.57 to −2.17) | 0.04 (−7.05 to 7.13) | 0.990 |
| PINS (mU/L) | −44.11 (−89.04 to 0.82) | −23.37 (−75.98 to 29.25) | −20.74 (−91.08 to 49.60) | 0.552 |
| HbA1c (%) | −0.28 (−0.41 to −0.15) | −0.06 (−0.20 to 0.09) | −0.23 (−0.42 to −0.03) | 0.027 |
| HOMA-IR | −1.84 (−2.95 to −0.74) | −1.63 (−2.83 to −0.44) | −0.21 (−1.84 to 1.42) | 0.794 |
| ALT (U/L) | −16.61 (−21.49 to −11.73) | −14.09 (−19.24 to −8.94) | −2.52 (−9.74 to 4.70) | 0.484 |
| AST (U/L) | −6.38 (−8.14 to −4.62) | −6.54 (−8.46 to −4.62) | 0.16 (−2.52 to 2.84) | 0.904 |
| TC (mmol/L) | −0.62 (−0.83 to −0.41) | −0.52 (−0.75 to −0.28) | −0.11 (−0.42 to 0.21) | 0.509 |
| TG (mmol/L) | −0.59 (−0.73 to −0.45) | −0.46 (−0.61 to −0.31) | −0.13 (−0.34 to 0.08) | 0.205 |
| LDL-c (mmol/L) | −0.37 (−0.54 to −0.21) | −0.38 (−0.56 to −0.21) | 0.01 (−0.23 to 0.25) | 0.949 |
| HDL-c (mmol/L) | −0.12 (−0.21 to −0.04) | −0.06 (−0.14 to 0.03) | −0.07 (−0.19 to 0.05) | 0.259 |
| Cr (umol/L) | −0.29 (−2.22 to 1.63) | 1.49 (−0.54 to 3.53) | −1.78 (−4.62 to 1.05) | 0.209 |
| SUA (umol/L) | −24.27 (−53.04 to 4.50) | −44.73 (−76.75 to −12.70) | 20.46 (−22.91 to 63.82) | 0.345 |
| LH (IU/L) | −0.56 (−4.66 to 3.54) | 3.33 (−1.10 to 7.75) | −3.89 (−9.98to 2.21) | 0.205 |
| FSH (IU/L) | −0.56 (−1.50 to 0.39) | 0.26 (−0.74 to 1.26) | −0.82 (−2.19 to 0.56) | 0.237 |
| PRL (mIU/L) | 57.91 (−27.24 to 143.06) | 7.76 (−85.04 to 100.55) | 50.15 (−75.82 to 176.13) | 0.423 |
| TT (nmol/L) | −0.06 (−0.26 to 0.14) | −0.22 (−0.43 to −0.01) | 0.16 (−0.13 to 0.45) | 0.274 |
| FT (pg/mL) | −0.04 (−0.57 to 0.48) | −0.35 (−0.93 to 0.22) | 0.31 (−0.48 to 1.10) | 0.427 |
| AD (ng/mL) | 0.04 (−0.63 to 0.71) | −0.62 (−1.23 to −0.02) | 0.67 (−0.24 to 1.57) | 0.143 |
| DHEAS (ug/dl) | 4.75 (−24.39 to 33.89) | 18.02 (−13.02 to 49.07) | −13.27 (−56.05 to 29.51) | 0.531 |
| SHBG (nmol/L) | −1.60 (−9.14 to 5.93) | 1.52 (−6.01 to 9.06) | −3.13 (−13.96 to 7.70) | 0.557 |
| FAI | 0.03 (0.01 to 0.04) | 0.04 (0.02 to 0.05) | −0.01 (−0.03 to 0.01) | 0.351 |
| CAP (dB/m) | −12.46 (−30.56 to 5.64) | −22.35 (−43.91 to −0.79) | 9.89 (−18.32 to 38.10) | 0.478 |
| LSM (kPa) | −0.83 (−1.53 to −0.13) | −0.35 (−1.18 to 0.48) | −0.49 (−1.57 to 0.60) | 0.368 |
| Total body fat (%) | −0.09 (−1.21 to 1.04) | 0.09 (−1.15 to 1.33) | −0.18 (−1.86 to 1.51) | 0.833 |
| Total body lean (%) | −0.20 (−1.33 to 0.92) | −0.36 (−1.63 to 0.91) | 0.16 (−1.55 to 1.87) | 0.852 |
| Total fat mass (kg) | −2.11 (−2.98 to −1.23) | −1.95 (−2.93 to −0.96) | −0.16 (−1.48 to 1.17) | 0.810 |
| Total lean mass (kg) | −3.14 (−3.98 to −2.31) | −2.77 (−3.71 to −1.82) | −0.38 (−1.64 to 0.88) | 0.548 |
| SAT mass (kg) | −0.25 (−0.35 to −0.14) | −0.17 (−0.29 to −0.06) | −0.07 (−0.23 to 0.08) | 0.351 |
Mean differences between the two treatment groups were presented as least-squares mean change with 95% CI. AD, androstenedione; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; Cr, creatinine; CRD, calorie-restricted diet; DBP, diastolic blood pressure; DHEAS, dehydroepiandrosterone sulfate; FAI, free androgen index; FINS, fasting insulin; FPG, fasting plasma glucose; FSH, follicle-stimulating hormone; FT, free testosterone; HbA1c, glycosylated hemoglobin A1c; HDL-c, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-c, low-density lipoprotein cholesterol; LH, luteinizing hormone; LS, least-squares; LSM, liver stiffness measurement; PCOS, polycystic ovary syndrome; PINS, postprandial insulin; PPG, postprandial plasma glucose; PRL, pituitary prolactin; SAT, subcutaneous adipose tissue; SBP, systolic blood pressure; SHBG, sex hormone-binding globulin; SUA, serum uric acid; TC, total Cholesterol; TG, triglyceride; TT, total testosterone; WC, waist circumference.